Fig. 6.

Genetic depletion of vascular endothelial growth factor receptor (VEGFR)2 delays tumor growth in the LN-308 but not in the LN-229 glioma model. (A,B) 75 000 LNT-229 or 100 000 LN-308 depleted of VEGFR2 or their shRNA control cells were implanted intracranially and monitored for survival (n = 7). (C, D) VEGFR2 gene silencing was confirmed by immunofluoresence microscopy at days 21 (LNT-229) or 37 (LN-308). Preservation of blood vessel labeling after tumor-specific gene silencing serves as an internal control. (E) LN-308 tumor sizes were determined based on H&E-stained sections (n = 3). (F) IHC for MMP9 levels upon VEGFR2 silencing. The mean area (a.u.) of MMP9-positive segments was reduced by ∼86% relative to control values (n = 3, P < .05).